Two-Week Interruption of Statin Therapy Results in an Exaggerated Inflammatory Monocyte Phenotype in Young Patients With Myocardial Infarction Without Standard Modifiable Risk Factors.
Abstract
In patients with myocardial infarction (MI) it is recommended to start high-intensity statin therapy as early as possible, irrespective of cholesterol concentration at presentation. This recommendation is often not followed in patient groups who are viewed as low risk because of the absence of traditional risk factors. In young patients with established atherosclerosis, statin treatment is initiated in only 22.4% of cases.1 Also, in patients who have experienced an ST-segment– elevation MI without standard modifiable risk factors (SMuRFs), there is lower use of statins at discharge. These patients have an increased risk of all-cause mortality, driven by an increase cardiovascular mortality, compared with patients with ST-segment– elevation MI with at least 1 traditional risk factor, whereas this increased risk is equalized when correcting for the lower use of statins.2
Authors: | Mol JQ, van Tuijl J, Bekkering S, Rodwell L, Pop GAM, Netea MG, van Royen N, Riksen NP, El Messaoudi S, |
---|---|
Journal: | J Am Heart Assoc;2024Apr16; 13 (8) 032978. doi:10.1161/JAHA.123.032978 |
Year: | 2024 |
PubMed: | PMID: 38563381 (Go to PubMed) |